Adding Kisqali (ribociclib) to a nonsteroidal aromatase inhibitor helped patients with hormone receptor–positive, HER2-negative early breast cancer live longer without their disease returning, ...
About 50% of menopausal women experience genitourinary syndrome of menopause (GSM) that involves changes to the genitals, ...
I am a healthy 69-year-old female. I walk every day and belong to an exercise group that I attend twice a week. I’m writing ...
“Treatment plays a significant role in long-term health after breast cancer; however, prevention is even more important and ...
A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last year's ...
The FDA has proposed removing the boxed warning for menopausal hormone therapy, focusing on local estrogen use and reassessing risks and benefits.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback